Enorama Pharma AB OMXSTO:ERMA:
DANIEL SCHRÖDER RESIGNS AS CEO OF ENORAMA PHARMA
BENGT JÖNSSON APPOINTED INTERIM CEO, ARA ABRAHAMIAN NEW CHAIRMAN
Enorama Pharma CEO Daniel Schröder Resigns
Earlier from Enorama Pharma
- ERMA: Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus
- ERMA: Losses deepened as Enorama Pharma restructures for US white snus growth and seeks new funding
- ERMA: Strong US snus growth offset by NRT write-down; urgent capital needs remain
- ERMA: Net sales rose sharply and losses narrowed as US pouch sales accelerated
- ERMA: US pouch sales drove revenue growth and improved liquidity, with narrowed losses
Later from Enorama Pharma
- Enorama Pharma Q3 Operating Loss Widens To SEK 12.3 Mln
- Bulletin from the extraordinary general meeting in Enorama Pharma AB (publ)
- Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision
- Enorama Pharma Postpones Its 2025 Year-End Report
- Enorama Pharma Enters Loan Agreement With DS Global
Follow Enorama Pharma into a list and get an email when it puts out news.
Follow Enorama Pharma